PL445128A1 - Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania - Google Patents

Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Info

Publication number
PL445128A1
PL445128A1 PL445128A PL44512823A PL445128A1 PL 445128 A1 PL445128 A1 PL 445128A1 PL 445128 A PL445128 A PL 445128A PL 44512823 A PL44512823 A PL 44512823A PL 445128 A1 PL445128 A1 PL 445128A1
Authority
PL
Poland
Prior art keywords
dione
pyrrole
hydroxyethyl
compounds
subject
Prior art date
Application number
PL445128A
Other languages
English (en)
Other versions
PL249318B1 (pl
Inventor
Janusz RACHOŃ
Mateusz Daśko
Karol Biernacki
Olga Ciupak
Sebastian DEMKOWICZ
Original Assignee
Politechnika Gdańska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Gdańska filed Critical Politechnika Gdańska
Priority to PL445128A priority Critical patent/PL249318B1/pl
Publication of PL445128A1 publication Critical patent/PL445128A1/pl
Publication of PL249318B1 publication Critical patent/PL249318B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku są związki chemiczne, będące akceptorami Michaela, charakteryzujące się strukturą chemiczną umożliwiającą ich wysoką reaktywność w reakcjach addycji Michaela, czyli addycji nukleofilowej do α,β-nienasyconych związków karbonylowych czy acylowych. Przedmiotem wynalazku jest pierwsze zastosowanie medyczne peptydowych pochodnych 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu. Przedmiotem wynalazku jest medyczne zastosowanie peptydowych pochodnych 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu jako leków, w tym zwłaszcza jako leków przeciwwirusowych o właściwościach inhibitora proteaz cysteinowych, w tym proteazy SARS CoV-2 Mpro oraz innych inhibitorów proteaz cysteinowych (zwanych również jako proteazy tiolowe). Wynalazek dotyczy również zastosowania tych związków do wykorzystania in vitro np. w diagnostyce jako inhibitorów proteazy cysteinowej, w tym proteazy SARS CoV-2 Mpro (ang. main protease- główna proteaza) oraz innych inhibitorów proteaz cysteinowych. W szczególności przedmiotowe związki peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu znajdują zastosowanie medyczne jako leki w terapii przeciwwirusowej, a w szczególności w leczeniu infekcji wirusowych wywołanych koronawirusem SARS CoV-2, w tym COVID19 oraz innych koronawirusów odpowiedzialnych za ciężki ostry zespół oddechowy (SARS), zwłaszcza ssaków, w tym ludzi. Przedmiotem wynalazku jest ponadto sposób otrzymywania tych nowych związków na bazie peptydowych pochodnych 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu. Wynalazek znajduje praktyczne zastosowanie w medycynie i diagnostyce.
PL445128A 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania PL249318B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445128A PL249318B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445128A PL249318B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Publications (2)

Publication Number Publication Date
PL445128A1 true PL445128A1 (pl) 2024-12-09
PL249318B1 PL249318B1 (pl) 2026-03-23

Family

ID=93799863

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445128A PL249318B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Country Status (1)

Country Link
PL (1) PL249318B1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432301A (zh) * 2020-11-03 2022-05-06 北京大学 一种共价抑制剂衍生物及其在治疗病毒感染方面的应用
WO2023283256A1 (en) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432301A (zh) * 2020-11-03 2022-05-06 北京大学 一种共价抑制剂衍生物及其在治疗病毒感染方面的应用
WO2023283256A1 (en) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IO ANTONOPOULOU, ELEFTHERIA SAPOUNTZAKI, ULRIKA ROVA, PAUL CHRISTAKOPOULOS: "Computational and Structural Biotechnology Journal, 2022, 20, 1306–1344", INHIBITION OF THE MAIN PROTEASE OF SARS-COV-2 (MPRO) BY REPURPOSING/DESIGNING DRUG-LIKE SUBSTANCES AND UTILIZING NATURE’S TOOLBOX OF BIOACTIVE COMPOUNDS *

Also Published As

Publication number Publication date
PL249318B1 (pl) 2026-03-23

Similar Documents

Publication Publication Date Title
Theoharides et al. Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
BR102021005055A2 (pt) detecção de anticorpos para sarsr-cov
CR20250420A (es) Inhibidores macrocíclicos de ras
MX2023014405A (es) Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii.
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
BRPI0510627A (pt) combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase
BRPI0317717B8 (pt) composto, composição farmacêutica, e uso de um composto
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
DE60314623D1 (de) Substituierte pyrazolopyrimidine
EA200801997A1 (ru) Новые соединения
BRPI0517564A (pt) métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica
MX2024009105A (es) Inhibidores de las cinasas cdk4/6.
CO2025001287A2 (es) Inhibidores de la proteasa principal de sars-cov2
MX2022014303A (es) Compuestos para el tratamiento del sars.
DOP2025000197A (es) Inhibidores de quinasa dependientes de ciclina (cdk2)
CO2023012342A2 (es) Inhibidores de enzimas